SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-20-001203
Filing Date
2020-01-22
Accepted
2020-01-22 08:10:53
Documents
11
Period of Report
2020-01-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nt10007476x1_8k.htm 8-K 35912
2 EXHIBIT 99.1 nt10007476x1_ex99-1.htm EX-99.1 36025
3 EXHIBIT 99.2 nt10007476x1_ex99-2.htm EX-99.2 15496
4 EXHIBIT 99.3 nt10007476x1_ex99-3.htm EX-99.3 16933
5 EXHIBIT 99.4 nt10007476x1_ex99-4.htm EX-99.4 14337
6 EXHIBIT 99.5 nt10007476x1_ex99-5.htm EX-99.5 38763
7 EXHIBIT 99.6 nt10007476x1_ex99-6.htm EX-99.6 32748
8 EXHIBIT 99.7 nt10007476x1_ex99-7.htm EX-99.7 15778
9 EXHIBIT 99.8 nt10007476x1_ex99-8.htm EX-99.8 12064
10 logo_cidara.jpg GRAPHIC 53997
11 nt10007476x1_ex99-7.jpg GRAPHIC 1269654
  Complete submission text file 0001140361-20-001203.txt   1977077
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 20537590
SIC: 2836 Biological Products, (No Diagnostic Substances)